Infectious Diseases News and Research

RSS

SIGA completes fourth human clinical trial of ST-246 smallpox antiviral drug candidate

SIGA Technologies, Inc., a company specializing in the development of pharmaceutical agents to combat bio-warfare pathogens, announced today the successful completion of its fourth human clinical trial, supporting the safety and tolerability of the anticipated clinical dose of ST-246®, SIGA's lead smallpox antiviral drug candidate.

23 Jun 2010

IQ Therapeutics achieves 100% survival in rabbit model at 48 hours after inhalation anthrax infection

IQ Therapeutics B.V., Groningen, the Netherlands, announced this week that in collaboration with the University of Texas Medical Branch it has obtained outstanding results for the treatment of inhalation anthrax. In a rabbit model up to 100% survival could be achieved with extended time to treatment (48h post infection) with a combination of two specific monoclonal antibodies developed by IQ Therapeutics. This has significant potential for saving lives of infected people who have no immediate access to treatment.

23 Jun 2010

MDI raises $1.4M as part of follow-on to its $3.3M Series C financing round

Molecular Detection Inc., a company developing Detect-Ready assays designed to increase the speed and accuracy of infectious disease diagnosis, today announced the first close of a new financing. The financing was led by MentorTech Ventures II, LP and included Robin Hood Ventures, Elm Spring Holdings and the Mid-Atlantic Angel Group Fund I and II, LP, all existing investors. The company raised $1.4 million as part of a follow-on to its $3.3 million Series C round announced in late 2009.

23 Jun 2010

Four new EVP grants awarded for interdisciplinary research to tackle environmental challenges

The Woods Institute for the Environment at Stanford University has awarded four new Environmental Venture Projects grants for interdisciplinary research aimed at finding practical solutions promoting global sustainability.

23 Jun 2010

ATP-driven bioluminescence predicts children at high risk for tooth decay: OHSU study

Researchers at the Oregon Health & Science University School of Dentistry have determined that ATP-driven (adenosine triphosphate-driven) bioluminescence - a way of measuring visible light generated from ATP contained in bacteria - is an innovative tool for rapidly assessing in children at the chair-side the number of oral bacteria and amount of plaque that can ultimately lead to tooth decay.

23 Jun 2010

NIH, Wellcome Trust partner to support population-based genetic studies of disorders, communicable diseases in Africa

The National Institutes of Health, an agency of the U.S. Department of Health and Human Services, and the Wellcome Trust, a global charity based in London, today announced a partnership to support population-based genetic studies in Africa of common, non-communicable disorders such as heart disease and cancer, as well as communicable diseases such as malaria.

22 Jun 2010

SynCon DNA vaccine shows advantages in magnitude and breadth of immune responses in non-human primates

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that the peer-reviewed journal Molecular Therapy has published a paper entitled "Comparative Analysis of Immune Responses Induced by Vaccination With SIV Antigens by Recombinant Ad5 Vector or Plasmid DNA in Rhesus Macaques." The paper, co-authored by researchers from Merck, University of Pennsylvania School of Medicine, and Inovio Pharmaceuticals, notes that significant advances in the design, formulation, and delivery of DNA plasmid-based vaccines have dramatically increased their ability to induce antigen-specific immune responses.

22 Jun 2010

NanoViricides' anti-Dengue drug candidates demonstrate potential against severe virus infection

NanoViricides, Inc. reports that its anti-Dengue drug candidates demonstrated significant protection in the initial animal survival studies of Dengue virus infection. The studies were performed in the laboratory of Dr. Eva Harris, Professor of Infectious Diseases at the University of California, Berkeley.

21 Jun 2010

Inovio Pharmaceuticals set to be added to Russell 3000 Index

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that the company is set to be added to the broad-market Russell 3000® Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on June 25, according to a preliminary list of additions updated on June 18 on www.russell.com.

21 Jun 2010

Beyond Moose and Mountains initiative focuses on building Canada's business and regulatory environment

At its 2010 annual general meeting in Montreal yesterday, the national biotechnology association, BIOTECanada, confirmed a national team of industry leaders, whose expertise will ensure Canada keeps growing what today is an $84 billion bio-economy.

21 Jun 2010

Exiqon licenses LNA technology to BD for diagnosing infectious diseases

Exiqon A/S, today announced that it has granted a non-exclusive license to BD to use Exiqon's proprietary locked nucleic acids technology in defined products for infectious disease diagnostics.

From BD (Becton, Dickinson and Company) 21 Jun 2010

Study examines ability of organisms to survive, sustain against various infectious diseases

"Robust" is an adjective appreciatively applied to certain vintage wines, but when describing viruses and pathogens, robustness is a property that may be much less desirable. It evokes drug resistant microbes and other superbugs that can wreak havoc as researchers struggle to deal with new pandemics. How can we undercut this robustness?

21 Jun 2010

U.S. releases statement on Global Health Initiative

The U.S. government continues to lay the groundwork for efforts under the U.S. Global Health Initiative (GHI), announcing the first round of "GHI Plus" countries, as well as the program's governance structure. GHI is a six-year, $63 billion initiative to help partner countries improve measurable health outcomes by strengthening health systems and building upon proven results. It places a particular focus on improving the health of women, newborns and children.

19 Jun 2010

HHS Secretary announces new $250M investment to improve health and well-being of Americans

U.S. Department of Health and Human Services Secretary Kathleen Sebelius today announced $250 million in new Affordable Care Act investments to support prevention activities and develop the nation's public health infrastructure.

19 Jun 2010

TFAH recognizes steps taken by Obama Administration on Prevention and Public Health Fund

Trust for America's Health today recognized the crucial first steps taken by the Obama Administration to allocate the recent health reform Act's Prevention and Public Health Fund, but acknowledged that in year one, half of the Fund's dollars were redirected outside the scope of its Congressional intent.

19 Jun 2010

Preclinical study shows treatment with DAS181 inhibits infection with multiple HPIV strains

NexBio, Inc. announced today the publication of a "Major Article" in the Journal of Infectious Diseases of a preclinical study showing that treatment with DAS181 (Fludase) inhibits infection with multiple human parainfluenza virus strains. DAS181 is a broad spectrum host-targeted investigational drug candidate for treatment and prevention of Influenza-Like Illness.

19 Jun 2010

Drug-resistant malaria spreading beyond Western Cambodia, U.S. malaria coordinator says

Resistance to artemisinin-based malaria medications seems to be spreading beyond western Cambodia, where it was first detected, U.S. global malaria coordinator Timothy Ziemer said during a visit to the region this week for a conference, Agence France-Presse reports.

19 Jun 2010

Brazil's deforestation linked to increased malaria incidence, study says

Deforestation in Brazil has been linked to an increase in malaria incidence there, according to findings published online Wednesday in the CDC journal, Emerging Infectious Diseases, Agence France-Presse reports.

19 Jun 2010

New partnership established to reduce newborn mortality

The U.S. Agency for International Development signed a Memorandum of Understanding this week with the Eunice Kennedy Shriver National Institute of Child Health and Human Development, Laerdal Medical AS, the American Academy of Pediatrics, and Save the Children. The objective of this Global Development Alliance is to reduce newborn mortality by expanding access to high-quality, affordable newborn resuscitation training materials and devices, improving the competence of birth attendants to resuscitate newborns, strengthening health systems and promoting global commitment and resources for life-saving newborn care.

19 Jun 2010

Children's Hospital Boston receives $2.4M Gates Foundation grant to develop novel neonatal vaccines

Children's Hospital Boston announced today that it has received a $2.4 million grant from the Bill & Melinda Gates Foundation. The grant will support the development of novel vaccines for newborns – research that is spearheaded by Ofer Levy, MD, Ph.D., a principal investigator in the Division of Infectious Diseases at Children's.

18 Jun 2010

Infectious Diseases News and Research

SIGA completes fourth human clinical trial of ST-246 smallpox antiviral drug candidate

IQ Therapeutics achieves 100% survival in rabbit model at 48 hours after inhalation anthrax infection

MDI raises $1.4M as part of follow-on to its $3.3M Series C financing round

Four new EVP grants awarded for interdisciplinary research to tackle environmental challenges

ATP-driven bioluminescence predicts children at high risk for tooth decay: OHSU study

NIH, Wellcome Trust partner to support population-based genetic studies of disorders, communicable diseases in Africa

SynCon DNA vaccine shows advantages in magnitude and breadth of immune responses in non-human primates

NanoViricides' anti-Dengue drug candidates demonstrate potential against severe virus infection

Inovio Pharmaceuticals set to be added to Russell 3000 Index

Beyond Moose and Mountains initiative focuses on building Canada's business and regulatory environment

Exiqon licenses LNA technology to BD for diagnosing infectious diseases

Study examines ability of organisms to survive, sustain against various infectious diseases

U.S. releases statement on Global Health Initiative

HHS Secretary announces new $250M investment to improve health and well-being of Americans

TFAH recognizes steps taken by Obama Administration on Prevention and Public Health Fund

Preclinical study shows treatment with DAS181 inhibits infection with multiple HPIV strains

Drug-resistant malaria spreading beyond Western Cambodia, U.S. malaria coordinator says

Brazil's deforestation linked to increased malaria incidence, study says

New partnership established to reduce newborn mortality

Children's Hospital Boston receives $2.4M Gates Foundation grant to develop novel neonatal vaccines

NGS for Infectious Disease Surveillance eBook

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News